Sacroiliitis Treatment Market

Market CAGR for sacroiliitis treatment is driven by the rising number of people who have arthritis. A few reasons fueling the growth of the market include the rising prevalence of rheumatoid arthritis worldwide, the introduction of novel therapeutic agents, and favorable reimbursement policies for expensive treatment products. The prevalence of rheumatoid arthritis (RA) was calculated to be 0.46 percent in the paper "The prevalence of rheumatoid arthritis (RA): a meta-analysis based on a systematic review" that was published in Rheumatology International in November 2020. The market will grow due to the increased adoption of therapies for treating RA.

An increase in diagnosed cases is anticipated as diagnostic capabilities and healthcare facilities in emerging nations improve. The market for sacroiliitis treatment is expected to develop due to this aspect during the forecast period. The aging population is predicted to increase demand for the product, as is patient and healthcare professional awareness of arthritis and ways to prevent it.

The main driver driving the market during the projected period is anticipated to be the rising usage of minimally invasive operations. Additionally, using new technology and improving diagnostic tools for sacroiliac joint problems will probably result in better SI joint fusion systems. Robotic surgery has become increasingly common in several medical device disciplines, including orthopedic devices. Sacroiliac joint fusion procedures can be carried out with more control and precision with the help of robotic equipment.

They provide benefits, including tactile feedback, enhanced visualization, and the capacity to carry out complicated movements in confined places, which lessen the procedure's invasiveness and may shorten the recovery period. Furthermore, superior implant designs and materials based on nanotechnology have been created for sacroiliac joint fusion. These implants are created precisely to offer stability, encourage fusion, and enable the best load transfer throughout the joint.

As more cutting-edge materials and technologies are used to develop superior and safer SI joint fusion systems, the market is anticipated to expand throughout the estimated time frame. This covers the usage of 3D-printed titanium implants and additive manufacturing. For instance, Genesys Spine's Siros Lateral Sacroiliac Joint Fusion system uses 3D-printed implants to stabilize best. The self-harvesting iFuse-3D implants by SI-BONE are titanium plasma spray-coated 3D implants that replicate native cancellous bone. These 3D-printed and additively made implants enable a linked, "bone-like" surface that might enhance osteointegration. Thus, driving the sacroiliitis treatment market revenue.

The aging population worldwide is a crucial factor influencing the Global Sacroiliitis Treatment Market Industry. Older adults are more susceptible to musculoskeletal disorders, including sacroiliitis, due to age-related degeneration of joints and connective tissues. As the global demographic shifts towards an older population, the demand for effective treatment options is likely to escalate. This trend is particularly pronounced in developed countries, where healthcare systems are increasingly focused on managing chronic conditions in the elderly. The growing geriatric demographic is expected to significantly contribute to the market's expansion in the coming years.

The increase in healthcare expenditure across various nations is a vital driver for the Global Sacroiliitis Treatment Market Industry. Governments and private sectors are investing more in healthcare infrastructure, leading to improved access to treatment options for patients suffering from sacroiliitis. Enhanced funding for research and development is also facilitating the introduction of innovative therapies. As healthcare systems evolve and prioritize musculoskeletal health, the market is poised for growth. This trend is particularly evident in regions with robust healthcare frameworks, where patients are more likely to receive timely and effective treatment.

The heightened awareness surrounding sacroiliitis and its symptoms is a key driver of the Global Sacroiliitis Treatment Market Industry. As healthcare professionals become more adept at recognizing the condition, early diagnosis and intervention are becoming more common. This shift is likely to lead to an increase in the number of patients seeking treatment, thereby expanding the market. Educational initiatives and campaigns aimed at both healthcare providers and the public are instrumental in this regard. Consequently, the growing recognition of sacroiliitis as a significant health issue is expected to bolster treatment demand and market growth.

The increasing incidence of sacroiliitis globally contributes significantly to the growth of the Global Sacroiliitis Treatment Market Industry. Factors such as sedentary lifestyles, obesity, and an aging population are leading to a rise in musculoskeletal disorders, including sacroiliitis. According to recent estimates, the prevalence of sacroiliitis is expected to rise, prompting a greater demand for effective treatment options. This trend is expected to drive the market value from 46.1 USD Billion in 2024 to an anticipated 295.7 USD Billion by 2035, reflecting a robust CAGR of 18.4% from 2025 to 2035.

Innovations in treatment modalities for sacroiliitis are propelling the Global Sacroiliitis Treatment Market Industry forward. The introduction of biologics, targeted therapies, and minimally invasive surgical techniques has transformed the management of this condition. These advancements not only enhance patient outcomes but also reduce recovery times, thereby increasing patient satisfaction. As healthcare providers adopt these novel therapies, the market is likely to witness substantial growth. The integration of technology in treatment protocols, such as telemedicine and digital health solutions, further supports this trend, making treatments more accessible to patients worldwide.

By region, the report gives market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American sacroiliitis treatment market area will dominate this market. The existence of important actors, a sophisticated healthcare infrastructure, and expanding reimbursement coverage can be credited for the region's high share. The area has a strong healthcare system, a sizable patient base, and a high prevalence of persistent lower back pain, frequently accompanied by sacroiliac joint dysfunction.

Further, the major countries studied in the market report are US, Canada, France, German, Italy, UK, Spain, Japan, China, Australia, India, South Korea, and Brazil.

Figure 3: SACROILIITIS TREATMENT MARKET SHARE BY REGION 2022 (USD Billion)

Source: Primary Research, Secondary Research, Market Research Future Database and Analyst Review

 Europe’s sacroiliitis treatment market accounts for the second-largest market share. The area has a strong healthcare system, a sizable patient base, and a high prevalence of persistent lower back pain, frequently accompanied by sacroiliac joint dysfunction. Further, the German sacroiliitis treatment market held the largest market share, and the UK sacroiliitis treatment market was the rapidly-growing market in the European region.

The Asia-Pacific Sacroiliitis Treatment Market is expected to grow at the fastest CAGR from 2023 to 2032. The market in this region is influenced by important aspects such as the expanding patient population, the high prevalence of chronic diseases, the building of healthcare infrastructure, and the rising levels of research and development in the biotechnology industry. The existence of significant market participants, including China, India, and Japan, fuels market expansion. Moreover, China’s sacroiliitis treatment market held the largest market share, and the Indian sacroiliitis treatment market was the rapidly-growing market in the Asia-Pacific region.

Leading market players are investing heavily in research and development to expand their product lines, which will help the sacroiliitis treatment market, grow even more. To increase their worldwide footprint, market participants are also engaging in various strategic actions. Important market developments include introducing new products, mergers and acquisitions, contractual agreements, increased investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, the sacroiliitis treatment industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics manufacturers use in the sacroiliitis treatment industry to benefit clients and increase the market sector. In recent years, the sacroiliitis treatment industry has offered some of the most significant advantages to medicine. Major players in the sacroiliitis treatment market, including Smith & Nephew Plc, Ipsen Group, Salix Pharmaceuticals, Johnson & Johnson, Pfizer, and others, are attempting to increase market demand by investing in research and development operations.

PainTEQ is a company that offers interventional pain treatment options for back pain and sacroiliac (SI) fusion. The company offers a SI joint stabilization device that offers SI joint dysfunction sufferers a safe, minimally invasive treatment for pain, assisting patients in eliminating chronic pain. In September 2021, PainTEQ announced the award of three additional U.S. patents specific to the LinQ treatment. The LinQ technique is a revolutionary, minimally invasive procedure developed to aid individuals with SI joint problems.

These patents cement PainTEQ's position as an industry leader in minimally invasive therapies for lower back pain related to the SI joint - a frequently misdiagnosed source of back pain that affects up to 30% of all lower back pain sufferers, or more than 10 million Americans each year.

Orthofix Medical Inc. is a medical device firm that provides orthopedic and spine solutions to physicians. spine, which includes bone growth and healing therapies, spinal implants, and regenerative tissue products, and orthopedics, which provides items used in fracture repair, deformity correction, and bone reconstruction operations, are the company's two primary segments. In June 2020, Orthofix Medical Inc. announced the FDA 510(k) clearance and the first patient implants of the FIREBIRDTM SI Fusion System. The FIREBIRD SI Fusion System is the first 3D-printed titanium bone screw launched in the United States to treat SI joint dysfunction.

It is designed to compress and stabilize the sacroiliac joint (SI joint) during fusion.